Benzene Ring Bonded Directly At The 2- Position Of The Diazole Ring Patents (Class 548/310.7)
  • Patent number: 9314456
    Abstract: Disclosed are compounds of formula (I): which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by, Clostridium difficile.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: April 19, 2016
    Assignee: SUMMIT THERAPEUTICS PLC
    Inventors: Francis Xavier Wilson, Peter David Johnson, Richard Vickers, Richard Storer, Graham Michael Wynne, Alan Geoffrey Roach, Olivier De Moor, Colin Richard Dorgan, Paul James Davis
  • Patent number: 9040572
    Abstract: This invention relates to a method of preparing a benzoimidazole derivative at high purity and high yield so as to enable the production of the benzoimidazole derivative compound as an antagonist against a vanilloid reactor-1, and particularly to a method of preparing a benzoimidazole derivative at high purity and high yield, wherein the benzoimidazole derivative is synthesized using a novel intermediate, namely, benzaldehyde, and thereby the preparation process is simple so that it can be applied to production.
    Type: Grant
    Filed: September 27, 2011
    Date of Patent: May 26, 2015
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: In Woo Kim, Ji Duck Kim, Hong Chul Yoon, Hee Kyoon Yoon, Byung Goo Lee, Joon Hwan Lee, Young Mook Lim, Soo Jin Choi
  • Patent number: 9024040
    Abstract: Provided are processes for the preparation of benzimidazole structures having Formula VIIIb-1: and salts and solvates thereof, wherein Z, X5, R2b, R2c and R10 are as defined herein. Compounds of Formula VIIIb-1 are useful for the preparation of benzimidazole derivatives.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: May 5, 2015
    Assignee: Array Biopharma Inc.
    Inventors: John DeMattei, Sagar Shakya, Anthony D. Piscopio, Bruno P. Hache, Matthew Charles Evans, James Gair Ford, Simon Mark Pointon, Koen Peeters, Timothy John Lilley, John Leonard
  • Publication number: 20150108449
    Abstract: An organic light-emitting material having the structure of formula (I) or (II) as described below and an organic light-emitting device (OLED) are disclosed. The OLED adopts the compound containing fluoranthene group as the electron transport material possessing good electron transport and injection ability. The material also enhances the luminous efficiency and lifetime of the device because of its excellent thermal stability and film-forming properties. At the same time, the high triplet energy and excellent electron transport capacity of the material containing fluoranthene group make it suitable to be used as the host for phosphorescent devices, increasing the number of electrons in the light-emitting layer and the efficiency of the device.
    Type: Application
    Filed: June 5, 2013
    Publication date: April 23, 2015
    Inventors: Jinhai Huang, Lei Dai, Jinxin Chen, Lifei Cai
  • Patent number: 9006454
    Abstract: The invention relates to compounds of formula (I) wherein R1, R2, X1, X2, Y, Ra, Rb, Q have the meanings given in claim 1. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis and also in the treatment of cancer disorders.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: April 14, 2015
    Assignee: Merck Serono S.A.
    Inventors: Siva Sanjeeva Rao Thunuguntla, Hosahalli Subramanya, Satish Reddy Kunnam, Sekhar Reddy Sanivaru Vijay, Chakrapani Bingi, Raviraj Kusanur, Matthias Schwarz, Michael Arlt
  • Publication number: 20150099890
    Abstract: Polyphenylene compounds such as compounds represented by Formula 1 may be used in electronic devices such as organic light-emitting devices. For example, the compounds may be used as host materials in a light-emitting layer.
    Type: Application
    Filed: December 12, 2014
    Publication date: April 9, 2015
    Inventors: Shijun Zheng, Liping Ma, Amane Mochizuki, Qianxi Lai, Sazzadur Rahman Khan, Sheng Li, Brett T. Harding, Hyunsik Chae, Rebecca Romero, David T. Sisk
  • Publication number: 20150087685
    Abstract: Methods and devices related to the treatment of diseases using phototherapy are described. Some embodiments provide an organic light-emitting diode device, such as a light-emitting device for phototherapy, comprising Ring System 1, Ring System 2, Ring System 3, Ring System 4 or Ring System 5. Methods of treating disease with phototherapy are also described.
    Type: Application
    Filed: April 12, 2013
    Publication date: March 26, 2015
    Inventors: Sazzadur Rahman Khan, Shijun Zheng, Sheng Li, Amane Mochizuki, Keisaku Okada
  • Patent number: 8975416
    Abstract: Disclosed are compounds of formula (I), which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by, Clostridium difficile.
    Type: Grant
    Filed: December 1, 2009
    Date of Patent: March 10, 2015
    Assignee: Summit Corporation PLC
    Inventors: Paul James Davis, Olivier De Moor, Colin Richard Dorgan, Peter David Johnson, Alan Geoffrey Roach, Richard Storer, Richard John Vickers, Francis Xavier Wilson, Graham Michael Wynne
  • Publication number: 20150034917
    Abstract: A heterocyclic compound of Formula 1 below and an organic light-emitting device including the same are provided. X1 to X4, L1, L2, n, m, and Ar1 to, Ar4 in Formula 1 are defined as in the specification.
    Type: Application
    Filed: March 24, 2014
    Publication date: February 5, 2015
    Applicants: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, SAMSUNG DISPLAY CO., LTD.
    Inventors: Se-Hun Kim, Mi-Kyung Kim, Jong-In Hong, Dong-Hyun Kim, Seong-Jin Jeong, Hwan-Hee Cho, Chang-Woong Chu
  • Patent number: 8933206
    Abstract: The present invention provides a new method for isolation and/or purification of immunoglobulins from a solution containing one or more immunoglobulins using a solid phase matrix represented by the formula: M-SP-L, wherein M is designates a matrix backbone, SP designates a spacer and L designates a substituted benzimidazole ligand.
    Type: Grant
    Filed: January 8, 2008
    Date of Patent: January 13, 2015
    Assignee: Millipore (U.K.) Limited
    Inventors: Gordon R. Duffin, Victoria Jane Dolan, Katherine Louise Angus, Andrew Lyddiatt
  • Patent number: 8933243
    Abstract: Polyphenylene compounds such as compounds represented by Formula I may be used in electronic devices such as organic light-emitting devices. For example, the compounds may be used as host materials in a light-emitting layer.
    Type: Grant
    Filed: June 22, 2011
    Date of Patent: January 13, 2015
    Assignee: Nitto Denko Corporation
    Inventors: Shijun Zheng, Liping Ma, Amane Mochizuki, Qianxi Lai, Sazzadur Rahman Khan, Sheng Li, Brett T. Harding, Hyunsik Chae, Rebecca Romero, David T. Sisk
  • Publication number: 20140364444
    Abstract: A fused heterocyclic compound the formula (1): wherein A1 represents —NR8—, and the like; A2 represents a nitrogen atom, and the like; A3 represents a nitrogen atom, and the like; R1 represents a C1-C6 chain hydrocarbon group optionally having one or more atoms or groups selected from Group X, and the like; R2, R3, R4, and R5 are same or different and represent independently a C1-C6 chain hydrocarbon group optionally having one or more halogen atoms, and the like; R6 and R7 are same or different and represent independently a C1-C6 chain hydrocarbon group optionally having one or more atoms or groups selected from Group X, and the like; R8 represents a C1-C6 chain hydrocarbon group optionally having one or more atoms or groups selected from Group W, and the like; n represents 0, 1 or 2. The compound has an excellent activity of controlling pests.
    Type: Application
    Filed: August 21, 2014
    Publication date: December 11, 2014
    Inventors: Hayato TAKYO, Masaki TAKAHASHI, Takamasa TANABE, Yoshihiko NOKURA, Mai ITO, Atsushi IWATA
  • Publication number: 20140363386
    Abstract: Compound with structure 2-phenylbenzimidazole of formula I and/or a pharmaceutically acceptable salt thereof, wherein said compound of formula I corresponds to: in which n is 1, 2 or 3 and in which R is a carboxyl radical (—COOH) or a sulphonic radical (—SO3H); pharmaceutical and/or cosmetic formulation and/or medical device including such a compound; method for synthesising it.
    Type: Application
    Filed: January 4, 2013
    Publication date: December 11, 2014
    Applicant: UNIVERSITA DEGLI STUDI DI FERRARA
    Inventors: Stefano Manfredini, Silvia Vertuani, Emanuela Scalambra
  • Patent number: 8901298
    Abstract: The present invention relates to condensed aromatic compounds with multiple ring bridging of the general formulae (1), (2), (3), (4) and (5). The invention furthermore relates to the use of the compounds according to the invention in an organic electronic device and to a process for the preparation of the compounds according to the invention. The invention furthermore relates to an electronic device which comprises the compounds according to the invention.
    Type: Grant
    Filed: October 1, 2009
    Date of Patent: December 2, 2014
    Assignee: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Christof Pflumm, Holger Heil, Arne Buesing
  • Publication number: 20140303370
    Abstract: A method of making ligands for producing novel heteroleptic iridium complexes is provided. The method includes reacting the condensation product of an aryl 1,2-diamine and an aryl aldehyde with manganese dioxide in a solvent. The novel iridium complexes produced using the ligands are useful compounds in OLED devices.
    Type: Application
    Filed: June 20, 2014
    Publication date: October 9, 2014
    Inventors: Gregg KOTTAS, Chuanjun Xia, Zeinab Elshenawy, Nasrin Ansari
  • Patent number: 8846947
    Abstract: Provided herein are sirtuin-modulating compounds of formula (II). The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders relating to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
    Type: Grant
    Filed: July 2, 2009
    Date of Patent: September 30, 2014
    Assignee: GlaxoSmithKline LLC
    Inventors: Chi B. Vu, Jeremy S. Disch, Pui Yee Ng, Charles A. Blum, Robert B. Perni
  • Publication number: 20140275224
    Abstract: Compounds and methods are provided for enhancing or boosting the transfection rate or efficiency of mammalian cells by foreign DNA, such as bacterial plasmid DNA. Compounds, including natural products and inventive synthetic compounds can increase the effectiveness of uptake and incorporation of foreign DNA by mammalian cells, such as human cells, by suppression of DNA cytosine deamination, which is believed to be a mechanism by which these cells eliminate foreign DNA. Inhibition of the cytosine deaminase enzymes by compounds as described herein serves to provide more effective transfection of eukaryotic cells by plasmids including engineered gene sequences. Transfection can be used to study cellular processes, or to cure genetic diseases in human patients. The inventive materials and methods increase the efficiency and effectiveness of such transfection techniques.
    Type: Application
    Filed: November 3, 2011
    Publication date: September 18, 2014
    Applicant: Regents of the University of Minnesota
    Inventors: Reuben S. Harris, Daniel A. Harki, Angela L. Perkins-Harki, Michael A. Carpenter, Ming Li
  • Patent number: 8835648
    Abstract: Heterocyclic compounds that modulate the hedgehog signaling pathway, pharmaceutical composition thereof and their therapeutic applications.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: September 16, 2014
    Assignee: Siena Biotech S.p.A.
    Inventors: J. Russell Thomas, Gal.la Pericot Mohr, Chiara Caramelli, Giacomo Minetto, Marta Bellini
  • Patent number: 8829200
    Abstract: The present invention relates to compounds of formula (IA) and (IB): and pharmaceutically acceptable salts thereof, wherein R1-R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: September 9, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Zhidong Chen, Stephane De Lombaert, Jonathon Alan Dines, Weimin Liu, Ho Yin Lo, Pui Leng Loke
  • Publication number: 20140243310
    Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
    Type: Application
    Filed: October 23, 2012
    Publication date: August 28, 2014
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Tohru Yamashita, Takuya Fujimoto, Ryo Mizojiri, Kazuko Yonemori, Hideki Hirose, Zenichi Ikeda, Ikuo Fujimori, Kyoko Toyofuku, Tsuneo Yasuma, Nobuyuki Matsunaga
  • Publication number: 20140239269
    Abstract: A pyrene-based compound, and an organic light-emitting diode including the pyrene-based compound are provided.
    Type: Application
    Filed: August 5, 2013
    Publication date: August 28, 2014
    Inventors: Eun-Jae Jeong, Seok-Hwan Hwang, Young-Kook Kim, Hye-Jin Jung, Jun-Ha Park, Eun-Young Lee, Jin-O Lim, Sang-Hyun Han, Soo-Yon Kim, Jong-Hyuk Lee
  • Publication number: 20140243331
    Abstract: This invention describes the development of targeted small molecule inhibitors of the inv(16) fusion, the causative agent in ˜12% of acute myeloid leukemia (AML). The inv(16) fusion results in expression of the CBF?-SMMHC fusion protein in the blood cells of afflicted patients. The present invention provides compounds which inhibit the function of both CBF? and the CBF?-SMMHC fusion. These compounds block the growth of an inv(16) leukemia cell line as well as increase its apoptosis, while showing minimal effects against non inv(16) cell lines. As a mechanism to develop inhibitors with selectivity for the CBF?-SMMHC fusion protein, the present invention further provides dimeric derivatives of these compounds which show both increased potency as well as selectivity for CBF?-SMMHC. These compounds show potent inhibition of an inv(16) leukemia cell line with minimal effects on non inv(16) cell lines.
    Type: Application
    Filed: May 7, 2014
    Publication date: August 28, 2014
    Applicant: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: John H. Bushweller, Jolanta Grembecka, Anuradha Illendula, Lauren Dixon
  • Publication number: 20140225070
    Abstract: Provided is an organic light-emitting diode including a compound of Formula 1 below: A detailed description of a substituent in Formula 1 above is defined as described in the detailed description.
    Type: Application
    Filed: June 21, 2013
    Publication date: August 14, 2014
    Applicant: Samsung Display Co., Ltd.
    Inventors: Jun-Ha Park, Seok-Hwan Hwang, Young-Kook Kim, Hye-Jin Jung, Eun-Young Lee, Jin-O Lim, Sang-Hyun Han, Eun-Jae Jeong, Soo-Yon Kim, Jong-Hyuk Lee
  • Publication number: 20140221332
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Application
    Filed: May 25, 2012
    Publication date: August 7, 2014
    Applicant: SUNOVION PHARMACEUTICALS INC.
    Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat
  • Patent number: 8790795
    Abstract: Provided are an organic compound having high heat stability suitable for use in an organic light-emitting device, and an organic light-emitting device using the organic compound. The organic light-emitting device is an organic light-emitting device, including: an anode; a cathode; and an organic compound layer disposed between the anode and the cathode, in which at least one layer of the organic compound layer has a 6,12-dinaphthylchrysene derivative represented by one of the following general formulae (1) and (2): in the formulae (1) and (2), Z represents a naphthyl group, and Q represents an electron-withdrawing substituent selected from the group consisting of the following general formulae (3) to (5): in the formula (5), R1 represents a hydrogen atom or a methyl group.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: July 29, 2014
    Assignee: Canon Kabushiki Kaisha
    Inventors: Hironobu Iwawaki, Hiroki Ohrui, Yuko Chishina, Masanori Muratsubaki, Tetsuo Takahashi
  • Patent number: 8771843
    Abstract: To provide a novel organic compound having a bipolar property. To reduce power consumption of a light-emitting element, a light-emitting device, and an electronic device. The organic compound has a fluorene skeleton and a structure in which an electron-accepting unit and a hole-accepting unit are bonded through carbon at the 9-position of the fluorene skeleton. The organic compound has a bipolar property and a large band gap. The use of the organic compound makes it possible to reduce power consumption of a light-emitting element, a light-emitting device, and an electronic device.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: July 8, 2014
    Assignee: Semiconductor Energy Laboratory Co., Ltd.
    Inventors: Satoshi Seo, Sachiko Kawakami, Harue Osaka
  • Publication number: 20140171363
    Abstract: The present invention provides compounds of formula (I); or pharmaceutically acceptable salts thereof, wherein the variables are defined as herein. The present invention provides a method for manufacturing the compounds of formula (I), their therapeutic uses, combinations with other of pharmacologically active agents, and a pharmaceutical compositions.
    Type: Application
    Filed: February 24, 2014
    Publication date: June 19, 2014
    Applicant: NOVARTIS AG
    Inventors: David Weninger BARNES, Gregory Raymond BEBERNITZ, Kevin CLAIRMONT, Scott Louis COHEN, Robert Edson DAMON, II, Robert Francis DAY, Stephanie Kay DODD, Christoph GAUL, Hatice Belgin GULGEZE EFTHYMIOU, Monish JAIN, Rajeshri Ganesh KARKI, Louise Clare KIRMAN, Kai LIN, Justin Yik Ching MAO, Tajesh Jayprakash PATEL, Brian Kenneth RAYMER, SU Liansheng
  • Publication number: 20140166988
    Abstract: The present invention discloses a novel organic compound is represented by the following formula(I), the organic EL device employing the organic compound as host material or dopant material of emitting layer and/or as electron transporting material can lower driving voltage, prolong half-lifetime and increase the efficiency. wherein m represent an integer of 0 to 10, n represent an integer of 0 to 2. X is a divalent bridge selected from the atom or group consisting from O, S, C(R5)2, N(R5), Si(R5)2. Ar, R1 to R4 are substituents and the same definition as described in the present invention.
    Type: Application
    Filed: December 17, 2012
    Publication date: June 19, 2014
    Applicant: LUMINESCENCE TECHNOLOGY CORPORATION
    Inventors: Feng-Wen Yen, Chen-Hao Chang
  • Publication number: 20140163237
    Abstract: Some embodiments provide a compound represented by Formula 1: wherein R1, R2, R3, R4, R5, R6, R7 and R8 are independently H, C1-C3 alkyl, or C1-3 perfluoroalkyl; HT is optionally substituted carbazoyl, optionally substituted phenylcarbazolyl, optionally substituted (phenylcarbazolyl)phenyl, optionally substituted phenylnaphthylamine, or optionally substituted diphenylamine; and ET optionally substituted benzimidazol-2-yl, optionally substituted benzothiazol-2-yl, optionally substituted benzoxazol-2-yl, optionally substituted 3,3?-bipyridin-5-yl, optionally substituted quinolin-8-yl, optionally substituted quinolin-5-yl, or optionally substituted quinoxalin-5-yl. Other embodiments provide an organic light-emitting diode device comprising a compound of Formula 1.
    Type: Application
    Filed: December 10, 2013
    Publication date: June 12, 2014
    Applicant: NITTO DENKO CORPORTION
    Inventors: David T. Sisk, Shijun Zheng
  • Publication number: 20140128408
    Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.
    Type: Application
    Filed: January 31, 2012
    Publication date: May 8, 2014
    Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Alan Kozikowski, Jay H. Kalin, Kyle V. Butier, Joel Bergman, Wayne W. Hancock
  • Publication number: 20140114076
    Abstract: The present invention relates to substituted benzo[c]phenanthrene derivatives and to the production and to the use thereof in electronic devices, and to the electronic devices themselves. The present invention relates in particular to benzo[c]phenanthrene derivatives substituted with at least one aromatic unit or at least one diarylamino unit.
    Type: Application
    Filed: January 2, 2014
    Publication date: April 24, 2014
    Applicant: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Arne Buesing, Holger Heil, Philipp Stoessel
  • Patent number: 8697736
    Abstract: Compound having formula (I) inhibit the PARP enzyme and are useful for treating a disease or a disorder associated with PARP. Also disclosed are pharmaceutical compositions comprising compounds having formula (I), methods of treatment comprising compounds having formula (I), and methods of inhibiting the PARP enzyme comprising compounds having formula (I).
    Type: Grant
    Filed: September 29, 2006
    Date of Patent: April 15, 2014
    Assignee: AbbVie Inc.
    Inventors: Thomas D. Penning, Sheela A. Thomas, Gui-Dong Zhu, Virajkumar B. Gandhi, Jianchun Gong, Vincent L. Giranda
  • Publication number: 20140080879
    Abstract: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.
    Type: Application
    Filed: September 20, 2012
    Publication date: March 20, 2014
    Applicant: PHARMACYCLICS, INC.
    Inventors: Daniel A. Dickman, Dange Vijay Kumar, Colin O'Bryan, Roopa Rai, William Dvorak Shrader
  • Publication number: 20140077175
    Abstract: A condensed-cyclic compound and an organic light-emitting diode including the condensed-cyclic compound.
    Type: Application
    Filed: March 13, 2013
    Publication date: March 20, 2014
    Applicant: SAMSUNG DISPLAY CO., LTD.
    Inventors: Hye-Jin Jung, Seok-Hwan Hwang, Young-Kook Kim, Jin-O Lim, Sang-Hyun Han, Eun-Jae Jeong, Soo-Yon Kim, Jun-Ha Park, Eun-Young Lee, Chang-Ho Lee, Jong-Hyuk Lee
  • Publication number: 20140066629
    Abstract: Aromatic azole compounds such as 2-(4-aminophenyl)-5-amino-benzimidazole are prepared in an organic sulfonic acid solvent instead of polyphosphoric acid. This allows recovery and recycle of the solvent and avoids the handling and environmental concerns resulting from the use of polyphosphoric acid. The resulting compounds find use in the pharmaceutical industry, as anticorrosion agents, and as precursors for high-performance fibers having high strength, stiffness, and flame resistance.
    Type: Application
    Filed: August 29, 2012
    Publication date: March 6, 2014
    Applicant: E I DU PONT DE NEMOURS AND COMPANY
    Inventors: MARC B. GOLDFINGER, TIMOTHY PELLENBARG
  • Publication number: 20140014885
    Abstract: The present invention relates to a novel non-polymeric organic ionic compound comprising one ion having a functional organic group, such as a matrix group, a hole injection group, a hole transport group, an electron injection group and an electron transport group, and comprising another ion preferably being so small that it may act as a mobile ion in films containing the organic ionic compound. Furthermore, the present invention relates to a composition containing the novel organic ionic compound and another functional compound. The novel organic ionic compound or the composition may be used in organic devices as functional materials, such as matrix materials or for materials charge transport. The resulting organic devices are also object of the present invention.
    Type: Application
    Filed: February 28, 2012
    Publication date: January 16, 2014
    Applicant: Merck Patent GmbH
    Inventors: Junyou Pan, Amir Hossain Parham
  • Publication number: 20140014925
    Abstract: A compound represented by Formula 1 below and an organic light-emitting device including the compound are provided: Substituents in Formula 1 are the same as defined in the specification.
    Type: Application
    Filed: June 21, 2013
    Publication date: January 16, 2014
    Inventors: Hye-Jin Jung, Seok-Hwan Hwang, Young-Kook Kim, Jin-O Lim, Sang-Hyun Han, Eun-Jae Jeong, Soo-Yon Kim, Jun-Ha Park, Eun-Young Lee, Chang-Ho Lee, Jong-Hyuk Lee
  • Publication number: 20140018368
    Abstract: The present invention provides compounds which antagonize hedgehog signaling and inhibit HDAC activity. The compounds can be used in methods of treating proliferative diseases and disorders such as cancer.
    Type: Application
    Filed: July 1, 2013
    Publication date: January 16, 2014
    Applicants: Genetech, Inc., Curis, Inc.
    Inventors: Xiong Cai, Changgeng Qian, Haixiao Zhai
  • Publication number: 20130296342
    Abstract: The present invention provides pharmaceutical compositions containing benzene compound(s) represented by General Formula (1) below and, particularly, LPL-activating compositions for use in hyperlipidemia therapeutic and preventive agents, anti-obesity agents, and the like: wherein R1, R2, R3 and R4 are as defined in the specification.
    Type: Application
    Filed: June 28, 2013
    Publication date: November 7, 2013
    Applicant: OTSUKA PHARMACEUTICAL FACTORY, INC.
    Inventors: Irina NEAGU, Michael OHLMEYER, Vidyadhar M. PARADKAR, Kurt W. SAIONZ, Koushi IWATA, Takashi OKAMURA, Tadao SHIBUTANI
  • Publication number: 20130284907
    Abstract: Disclosed herein are compounds represented by Formula 1, wherein R1, Ar1, X, Ar2, Ar3, and Het are described herein. Compositions and light-emitting devices related thereto are also disclosed.
    Type: Application
    Filed: June 24, 2013
    Publication date: October 31, 2013
    Inventors: Shijun Zheng, Jensen Cayas, Sheng Li, Amane Mochizuki, Hyun Sik Chae, Brett T. Harding
  • Publication number: 20130274471
    Abstract: A compound for an organic photoelectric device, an organic photoelectric device including the same, and a display device including the same the compound being represented by the following Chemical Formula 1:
    Type: Application
    Filed: June 12, 2013
    Publication date: October 17, 2013
    Inventors: Kyu-Yeon IN, Myeong-Soon KANG, Ho-Kuk JUNG, Nam-Soo KIM, Eui-Su KANG, Mi-Young CHAE, Jin-Seong PARK
  • Publication number: 20130256641
    Abstract: A benzimidazole compound, an organic photoelectric device, and a display element, the benzimidazole compound being represented by the following Chemical Formula 1:
    Type: Application
    Filed: May 13, 2013
    Publication date: October 3, 2013
    Inventors: Mi-Young Chae, Seung-Gyoung Lee, Ho-Jae Lee, Hyung-Sun Kim, Sung-Hyun Jung, Ja-Hyun Kim, Eun-Sun Yu
  • Publication number: 20130245064
    Abstract: The invention relates to novel acylamino-hydroxy-benzamides of formula (I), wherein R1 is phenyl substituted by phenyl, phenoxy, phenylamino or heteroaryl, all optionally further substituted; bicyclic aryl, monocyclic heteroaryl substituted by optionally substituted phenyl, or bicyclic heteroaryl, R2 is hydrogen or methyl, and R3 and R4 have the meanings indicated in the description. These compounds are useful for the treatment and/or prophylaxis of skeletal muscle atrophy, schizophrenia and Alzheimer's disease, and as cognitive enhancers.
    Type: Application
    Filed: October 31, 2011
    Publication date: September 19, 2013
    Inventors: Shaheen Ahmed, Stefan Hettwer, Jan Willem Vrijbloed, Carlo Farina, Piero Paravidino
  • Publication number: 20130231477
    Abstract: This invention relates to a method of preparing a benzoimidazole derivative at high purity and high yield so as to enable the production of the benzoimidazole derivative compound as an antagonist against a vanilloid reactor-1, and particularly to a method of preparing a benzoimidazole derivative at high purity and high yield, wherein the benzoimidazole derivative is synthesized using a novel intermediate, namely, benzaldehyde, and thereby the preparation process is simple so that it can be applied to production.
    Type: Application
    Filed: September 27, 2011
    Publication date: September 5, 2013
    Applicant: DAEWOONG PHARMACEUTICAL CO., LTD.
    Inventors: In Woo Kim, Ji Duck Kim, Hong Chul Yoon, Hee Kyoon Yoon, Byung Goo Lee, Joon Hwan Lee, Young Mook Lim, Soo Jin Choi
  • Patent number: 8501957
    Abstract: Benzimidazole compounds of formula (I): wherein R1, R2, R3, R4, R5, X, Y, Z1, and Z2 are defined herein. Also disclosed is a method for treating cancer with benzimidazole compounds.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: August 6, 2013
    Assignee: China Medical University
    Inventors: Chih-Shiang Chang, Jih-Hwa Guh, Che-Ming Teng, Shiow-Lin Pan, Wei-Ling Chang, Ju-Fang Liu, Kai-Wei Chang, Sheng-Chu Kuo
  • Patent number: 8501956
    Abstract: Provided are compounds having Formula VIIIa-1: wherein Z, X5, R2, R2a and R10 are as defined herein. Compounds of Formula VIIIa-1 can be used to prepare heterocyclic derivatives such as benzimidazole derivatives.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: August 6, 2013
    Assignees: Array BioPharma Inc., AstraZeneca SB
    Inventors: John Demattei, Sagar Shakya, Anthony D. Piscopio, Bruno P. Hache, Matthew Charles Evans, James Gair Ford, Simon Mark Pointon, Koen Peeters, Timothy John Lilley, John Leonard
  • Publication number: 20130190350
    Abstract: The present invention makes available methods and reagents for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function comprising contacting the cell with a hedgehog antagonist, such as a small molecule, in a sufficient amount to aberrant growth state, e.g., to agonize a normal ptc pathway or antagonize smoothened or hedgehog activity.
    Type: Application
    Filed: December 12, 2012
    Publication date: July 25, 2013
    Applicant: CURIS, INC.
    Inventor: Curis, Inc.
  • Publication number: 20130172570
    Abstract: This present invention provides a method of making benzazoles comprising a process of making aryl or alkyl benzazoles from corresponding aryl acid chlorides or alkyl acid chlorides without applying hazard condensing agent. The benzazole compounds described in this invention have following formula I: Wherein: n is an integer of from 3 to 8; Z is O, NR or S; and R and R? are individually hydrogen; alkyl of from 1 to 24 carbon atoms, for example, propyl, t-butyl, heptyl, and the like; aryl or hetero-atom substituted aryl of from 5 to 20 carbon atoms, for example, phenyl and naphthyl, furyl, thienyl, pyridyl, quinolinyl and other heterocyclic systems; or halo such as chloro, fluoro, bromo, cyano; or atoms necessary to complete a fused aromatic ring; and B is a linkage unit consisting of alkyl, aryl, substituted alkyl, or substituted aryl which conjugately or unconjugately connects the multiple benzazoles together.
    Type: Application
    Filed: February 15, 2012
    Publication date: July 4, 2013
    Applicant: US Government as Represented by the Secretary of the ARMY
    Inventors: Jianmin Shi, Eric W. Forsythe, David C. Morton
  • Publication number: 20130158089
    Abstract: Treatment of cancer and thromboembolic disorders using inhibitors of Factor VIIa are disclosed herein using a compound of Formula I:
    Type: Application
    Filed: November 2, 2012
    Publication date: June 20, 2013
    Applicant: PHARMACYCLICS, INC.
    Inventor: Pharmacyclics, Inc
  • Publication number: 20130146856
    Abstract: Compounds including optionally substituted Ring Systems 1-4 may be used as host in light-emitting devices.
    Type: Application
    Filed: February 7, 2013
    Publication date: June 13, 2013
    Applicant: NITTO DENKO CORPORATION
    Inventor: Nitto Denko Corporation